SCHEMBL21052173

SCHEMBL21052173

CC(C)(S)CC(=O)N/N=C1/CCCc2cc(OCCC(C(=O)O)N3C(=O)CCC3=O)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ SMN1; SMN2 Q16637 5/20 0.38
▸ GRK2 P25098 4/20 0.38
▸ ROCK2 O75116 3/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ POLB P06746 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21052022 0.87 MAPT (0.32) MAPTHTTKMT2AMEN1SMN1; SMN2
SCHEMBL22802058 0.86 NPC1 (0.33) MAPTHTTKMT2AMEN1SMN1; SMN2
SCHEMBL29527619 0.85 MAPT (0.30) MAPTALDH1A1
SCHEMBL21098730 0.82 MAPT (0.46) MAPTHTTKMT2AMEN1SMN1; SMN2
SCHEMBL22802046 0.82 MAPT (0.46) MAPTHTTKMT2AMEN1SMN1; SMN2
SCHEMBL22802047 0.82 MAPT (0.46) MAPTHTTKMT2AMEN1SMN1; SMN2
SCHEMBL22802050 0.82 MAPT (0.44) MAPTHTTKMT2AMEN1SMN1; SMN2
SCHEMBL21098675 0.82 MAPT (0.44) MAPTHTTKMT2AMEN1SMN1; SMN2
SCHEMBL21052423 0.82 MAPT (0.44) MAPTHTTKMT2AMEN1SMN1; SMN2
SCHEMBL21098677 0.82 MAPT (0.44) MAPTHTTKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11576981-B2 Acyl hydrazone linkers, methods and uses thereof ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2023-02-14 — — US disclosed
US-20200397916-A1 ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2020-12-24 — — US disclosed
EP-3720842-A1 ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF Ontario Institute For Cancer Research (CA) 2020-10-14 — — EP disclosed
WO-2019109188-A1 ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2019-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200397916-A1 ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF KAT7, AADAC, HDAC7 MAPT 3413/4885HTT 1430/4885KMT2A 1440/4885
US-11576981-B2 Acyl hydrazone linkers, methods and uses thereof AADAC, HDAC8, KAT8 MAPT 3082/4885HTT 1574/4885KMT2A 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback